{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T07:46:23Z","timestamp":1768463183818,"version":"3.49.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2014,4,15]],"date-time":"2014-04-15T00:00:00Z","timestamp":1397520000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1007\/s00417-014-2626-2","type":"journal-article","created":{"date-parts":[[2014,4,14]],"date-time":"2014-04-14T00:34:18Z","timestamp":1397435658000},"page":"943-949","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Blockade of the VEGF isoforms in inflammatory corneal hemangiogenesis and lymphangiogenesis"],"prefix":"10.1007","volume":"252","author":[{"given":"Melanie","family":"Lipp","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franziska","family":"Bucher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anand","family":"Parthasarathy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deniz","family":"Hos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jasmine","family":"Onderka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claus","family":"Cursiefen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felix","family":"Bock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,4,15]]},"reference":[{"key":"2626_CR1","doi-asserted-by":"crossref","first-page":"11405","DOI":"10.1073\/pnas.0506112103","volume":"103","author":"C Cursiefen","year":"2006","unstructured":"Cursiefen C, Chen L, Saint-Geniez M, Hamrah P, Jin Y, Rashid S, Pytowski B, Persaud K, Wu Y, Streilein JW, Dana R (2006) Nonvascular VEGF receptor 3 expression by corneal epithelium maintains avascularity and vision. Proc Natl Acad Sci U S A 103:11405\u201311410. doi: 10.1073\/pnas.0506112103","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2626_CR2","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/00055735-200108000-00002","volume":"12","author":"JH Chang","year":"2001","unstructured":"Chang JH, Gabison EE, Kato T, Azar DT (2001) Corneal neovascularization. Curr Opin Ophthalmol 12:242\u2013249","journal-title":"Curr Opin Ophthalmol"},{"key":"2626_CR3","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1167\/iovs.03-0940","volume":"45","author":"C Cursiefen","year":"2004","unstructured":"Cursiefen C, Masli S, Ng TF, Dana MR, Bornstein P, Lawler J, Streilein JW (2004) Roles of thrombospondin\u22121 and \u22122 in regulating corneal and iris angiogenesis. Invest Ophthalmol Vis Sci 45:1117\u20131124","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2626_CR4","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/00003226-200304000-00021","volume":"22","author":"C Cursiefen","year":"2003","unstructured":"Cursiefen C, Chen L, Dana MR, Streilein JW (2003) Corneal lymphangiogenesis: evidence, mechanisms, and implications for corneal transplant immunology. Cornea 22:273\u2013281","journal-title":"Cornea"},{"key":"2626_CR5","first-page":"2176","volume":"36","author":"Y Sano","year":"1995","unstructured":"Sano Y, Ksander BR, Streilein JW (1995) Fate of orthotopic corneal allografts in eyes that cannot support anterior chamber-associated immune deviation induction. Invest Ophthalmol Vis Sci 36:2176\u20132185","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2626_CR6","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1096\/fj.02-0319com","volume":"16","author":"R Cao","year":"2002","unstructured":"Cao R, Brakenhielm E, Li X, Pietras K, Widenfalk J, Ostman A, Eriksson U, Cao Y (2002) Angiogenesis stimulated by PDGF-CC, a novel member in the PDGF family, involves activation of PDGFR-alphaalpha and -alphabeta receptors. FASEB J 16:1575\u20131583. doi: 10.1096\/fj.02\u20130319com","journal-title":"FASEB J"},{"key":"2626_CR7","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1167\/iovs.07-1314","volume":"49","author":"D Hos","year":"2008","unstructured":"Hos D, Bock F, Dietrich T, Onderka J, Kruse FE, Thierauch KH, Cursiefen C (2008) Inflammatory corneal (lymph) angiogenesis is blocked by VEGFR-tyrosine kinase inhibitor ZK 261991, resulting in improved graft survival after corneal transplantation. Invest Ophthalmol Vis Sci 49:1836\u20131842. doi: 10.1167\/iovs.07\u20131314","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2626_CR8","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00417-007-0684-4","volume":"246","author":"F Bock","year":"2008","unstructured":"Bock F, Konig Y, Kruse F, Baier M, Cursiefen C (2008) Bevacizumab (Avastin) eye drops inhibit corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 246:281\u2013284. doi: 10.1007\/s00417\u2013007\u20130684\u20134","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2626_CR9","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1167\/iovs.03-1380","volume":"45","author":"C Cursiefen","year":"2004","unstructured":"Cursiefen C, Cao J, Chen L, Liu Y, Maruyama K, Jackson D, Kruse FE, Wiegand SJ, Dana MR, Streilein JW (2004) Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival. Invest Ophthalmol Vis Sci 45:2666\u20132673. doi: 10.1167\/iovs.03\u201313800","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2626_CR10","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1167\/iovs.06-0570","volume":"48","author":"F Bock","year":"2007","unstructured":"Bock F, Onderka J, Dietrich T, Bachmann B, Kruse FE, Paschke M, Zahn G, Cursiefen C (2007) Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Invest Ophthalmol Vis Sci 48:2545\u20132552. doi: 10.1167\/iovs.06\u20130570","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2626_CR11","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1002\/jcb.21579","volume":"102","author":"EC Breen","year":"2007","unstructured":"Breen EC (2007) VEGF in biological control. J Cell Biochem 102:1358\u20131367. doi: 10.1002\/jcb.21579","journal-title":"J Cell Biochem"},{"key":"2626_CR12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/OPTH.S1959","volume":"2","author":"MS Spitzer","year":"2008","unstructured":"Spitzer MS, Ziemssen F, Bartz-Schmidt KU, Gelisken F, Szurman P (2008) Treatment of age-related macular degeneration: focus on ranibizumab. Clin Ophthalmol 2:1\u201314","journal-title":"Clin Ophthalmol"},{"key":"2626_CR13","doi-asserted-by":"crossref","first-page":"417","DOI":"10.4103\/0301-4738.36474","volume":"55","author":"S Grisanti","year":"2007","unstructured":"Grisanti S, Ziemssen F (2007) Bevacizumab: off-label use in ophthalmology. Indian J Ophthalmol 55:417\u2013420","journal-title":"Indian J Ophthalmol"},{"key":"2626_CR14","doi-asserted-by":"crossref","first-page":"18902","DOI":"10.1073\/pnas.0509069102","volume":"102","author":"JH Lee","year":"2005","unstructured":"Lee JH, Canny MD, De Erkenez A, Krilleke D, Ng YS, Shima DT, Pardi A, Jucker F (2005) A therapeutic aptamer inhibits angiogenesis by specifically targeting the heparin binding domain of VEGF165. Proc Natl Acad Sci U S A 102:18902\u201318907. doi: 10.1073\/pnas.0509069102","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2626_CR15","doi-asserted-by":"crossref","first-page":"20556","DOI":"10.1074\/jbc.273.32.20556","volume":"273","author":"J Ruckman","year":"1998","unstructured":"Ruckman J, Green LS, Beeson J, Waugh S, Gillette WL, Henninger DD, Claesson-Welsh L, Janjic N (1998) Two-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J Biol Chem 273:20556\u201320567","journal-title":"J Biol Chem"},{"key":"2626_CR16","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/nrd1677","volume":"4","author":"SL Fine","year":"2005","unstructured":"Fine SL, Martin DF, Kirkpatrick P (2005) Pegaptanib sodium. Nat Rev Drug Discov 4:187\u2013188. doi: 10.1038\/nrd1677","journal-title":"Nat Rev Drug Discov"},{"key":"2626_CR17","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1167\/iovs.07-0195","volume":"49","author":"M Ju","year":"2008","unstructured":"Ju M, Mailhos C, Bradley J, Dowie T, Ganley M, Cook G, Calias P, Lange N, Adamis AP, Shima DT, Robinson GS (2008) Simultaneous but not prior inhibition of VEGF165 enhances the efficacy of photodynamic therapy in multiple models of ocular neovascularization. Invest Ophthalmol Vis Sci 49:662\u2013670. doi: 10.1167\/iovs.07\u20130195","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2626_CR18","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1097\/01.ico.0000183485.85636.ff","volume":"25","author":"C Cursiefen","year":"2006","unstructured":"Cursiefen C, Maruyama K, Jackson DG, Streilein JW, Kruse FE (2006) Time course of angiogenesis and lymphangiogenesis after brief corneal inflammation. Cornea 25:443\u2013447. doi: 10.1097\/01.ico.0000183485.85636.ff","journal-title":"Cornea"},{"key":"2626_CR19","first-page":"e1501","volume":"113","author":"U Chakravarthy","year":"2006","unstructured":"Chakravarthy U, Adamis AP, Cunningham ET Jr, Goldbaum M, Guyer DR, Katz B, Patel M (2006) Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology 113:e1501\u20131525. doi: 10.1016\/j.ophtha.2006.02.064 , 1508","journal-title":"Ophthalmology"},{"key":"2626_CR20","unstructured":"http:\/\/www.mrcophth.com\/macugen.htm (2014\u201303\u201319)"},{"key":"2626_CR21","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.exer.2008.08.007","volume":"87","author":"F Bock","year":"2008","unstructured":"Bock F, Onderka J, Hos D, Horn F, Martus P, Cursiefen C (2008) Improved semiautomatic method for morphometry of angiogenesis and lymphangiogenesis in corneal flatmounts. Exp Eye Res 87:462\u2013470. doi: 10.1016\/j.exer.2008.08.007","journal-title":"Exp Eye Res"},{"key":"2626_CR22","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1172\/JCI20465","volume":"113","author":"C Cursiefen","year":"2004","unstructured":"Cursiefen C, Chen L, Borges LP, Jackson D, Cao J, Radziejewski C, D\u2019Amore PA, Dana MR, Wiegand SJ, Streilein JW (2004) VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J Clin Invest 113:1040\u20131050. doi: 10.1172\/JCI20465","journal-title":"J Clin Invest"},{"key":"2626_CR23","first-page":"18","volume":"39","author":"S Amano","year":"1998","unstructured":"Amano S, Rohan R, Kuroki M, Tolentino M, Adamis AP (1998) Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization. Invest Ophthalmol Vis Sci 39:18\u201322","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2626_CR24","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1136\/bjo.2006.107912","volume":"91","author":"RP Manzano","year":"2007","unstructured":"Manzano RP, Peyman GA, Khan P, Carvounis PE, Kivilcim M, Ren M, Lake JC, Chevez-Barrios P (2007) Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin). Br J Ophthalmol 91:804\u2013807. doi: 10.1136\/bjo.2006.107912","journal-title":"Br J Ophthalmol"},{"key":"2626_CR25","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nrd1955","volume":"5","author":"EW Ng","year":"2006","unstructured":"Ng EW, Shima DT, Calias P, Cunningham ET Jr, Guyer DR, Adamis AP (2006) Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov 5:123\u2013132. doi: 10.1038\/nrd1955","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"2626_CR26","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/j.1755-3768.2012.02525.x","volume":"92","author":"F Bucher","year":"2014","unstructured":"Bucher F, Parthasarathy A, Bergua A, Onderka J, Regenfuss B, Cursiefen C, Bock F (2014) Topical Ranibizumab inhibits inflammatory corneal hem- and lymphangiogenesis. Acta Ophthalmol 92(2):143\u2013148. doi: 10.1111\/j.1755\u20133768.2012.02525.x","journal-title":"Acta Ophthalmol"},{"key":"2626_CR27","doi-asserted-by":"crossref","first-page":"3870","DOI":"10.1167\/iovs.07-1418","volume":"49","author":"CQ Yu","year":"2008","unstructured":"Yu CQ, Zhang M, Matis KI, Kim C, Rosenblatt MI (2008) Vascular endothelial growth factor mediates corneal nerve repair. Invest Ophthalmol Vis Sci 49:3870\u20133878. doi: 10.1167\/iovs.07\u20131418","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2626_CR28","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1167\/iovs.09-4937","volume":"51","author":"EC Kim","year":"2010","unstructured":"Kim EC, Lee WS, Kim MS (2010) The inhibitory effects of bevacizumab eye drops on NGF expression and corneal wound healing in rats. Invest Ophthalmol Vis Sci 51:4569\u20134573. doi: 10.1167\/iovs.09\u20134937","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2626_CR29","doi-asserted-by":"crossref","first-page":"4653","DOI":"10.1167\/iovs.08-2805","volume":"50","author":"TI Kim","year":"2009","unstructured":"Kim TI, Chung JL, Hong JP, Min K, Seo KY, Kim EK (2009) Bevacizumab application delays epithelial healing in rabbit cornea. Invest Ophthalmol Vis Sci 50:4653\u20134659. doi: 10.1167\/iovs.08\u20132805","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2626_CR30","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1136\/bjo.2006.099598","volume":"90","author":"AE Fung","year":"2006","unstructured":"Fung AE, Rosenfeld PJ, Reichel E (2006) The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 90:1344\u20131349. doi: 10.1136\/bjo.2006.099598","journal-title":"Br J Ophthalmol"},{"key":"2626_CR31","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1159\/000323943","volume":"225","author":"AM Carneiro","year":"2011","unstructured":"Carneiro AM, Barthelmes D, Falcao MS, Mendonca LS, Fonseca SL, Goncalves RM, Faria-Correia F, Falcao-Reis FM (2011) Arterial thromboembolic events in patients with exudative age-related macular degeneration treated with intravitreal bevacizumab or ranibizumab. Ophthalmologica 225:211\u2013221. doi: 10.1159\/000323943","journal-title":"Ophthalmologica"},{"key":"2626_CR32","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1136\/bjo.2009.178574","volume":"95","author":"C Schmucker","year":"2011","unstructured":"Schmucker C, Loke YK, Ehlken C, Agostini HT, Hansen LL, Antes G, Lelgemann M (2011) Intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a safety review. Br J Ophthalmol 95:308\u2013317. doi: 10.1136\/bjo.2009.178574","journal-title":"Br J Ophthalmol"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-014-2626-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00417-014-2626-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-014-2626-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T19:40:40Z","timestamp":1559072440000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00417-014-2626-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,15]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["2626"],"URL":"https:\/\/doi.org\/10.1007\/s00417-014-2626-2","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,15]]}}}